These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27385523)

  • 41. Rotigotine transdermal system for perioperative administration.
    Korczyn AD; Reichmann H; Boroojerdi B; Häck HJ
    J Neural Transm (Vienna); 2007 Feb; 114(2):219-21. PubMed ID: 17177076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transdermal therapy in Parkinson's disease.
    Korczyn AD
    Lancet Neurol; 2007 Jun; 6(6):475-6. PubMed ID: 17509476
    [No Abstract]   [Full Text] [Related]  

  • 43. [Local effects of transdermal treatment with rotigotine].
    Bermejo PE; Zea MA; Alba-Alcántara L; Ruiz-Huete C
    Rev Neurol; 2013 Apr; 56(7):359-62. PubMed ID: 23520004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rotigotine for the treatment of Parkinson's disease.
    Morgan JC; Sethi KD
    Expert Rev Neurother; 2006 Sep; 6(9):1275-82. PubMed ID: 17009915
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
    Lyons KE; Pahwa R
    Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rotigotine Transdermal Patch: A Review in Parkinson's Disease.
    Frampton JE
    CNS Drugs; 2019 Jul; 33(7):707-718. PubMed ID: 31243728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
    Naidu Y; Chaudhuri KR
    Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.
    Garnock-Jones KP
    Drugs; 2016 Jul; 76(10):1031-40. PubMed ID: 27324269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
    Watts RL; Jankovic J; Waters C; Rajput A; Boroojerdi B; Rao J
    Neurology; 2007 Jan; 68(4):272-6. PubMed ID: 17202432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
    Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
    Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
    LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
    Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A controlled trial of rotigotine monotherapy in early Parkinson's disease.
    Parkinson Study Group
    Arch Neurol; 2003 Dec; 60(12):1721-8. PubMed ID: 14676046
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder.
    Liguori C; Placidi F; Stefani A; Mercuri NB; Marciani MG; Stanzione P; Pierantozzi M
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1476-8. PubMed ID: 26578038
    [No Abstract]   [Full Text] [Related]  

  • 54. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contact leukoderma induced by rotigotine transdermal patch (Neupro®).
    Takeuchi A; Egawa G; Nomura T; Kabashima K
    Eur J Dermatol; 2019 Apr; 29(2):215-217. PubMed ID: 30734716
    [No Abstract]   [Full Text] [Related]  

  • 56. Spotlight on rotigotine transdermal patch in Parkinson's disease.
    Sanford M; Scott LJ
    Drugs Aging; 2011 Dec; 28(12):1015-7. PubMed ID: 22117099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pharmacology sheet. Transdermal Rotigotine (Neupro)].
    J Pharm Belg; 2010 Jun; (2):49-50. PubMed ID: 20623986
    [No Abstract]   [Full Text] [Related]  

  • 58. Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.
    Chung SJ; Asgharnejad M; Bauer L; Benitez A; Boroojerdi B; Heidbrede T; Little A; Kim HJ
    Expert Rev Neurother; 2017 Jul; 17(7):737-749. PubMed ID: 28548894
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease.
    Chitnis S; Jaffery M; Dewey RB
    Int J Neurosci; 2012 Jan; 122(1):22-5. PubMed ID: 21864207
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline.
    Ghys L; Surmann E; Whitesides J; Boroojerdi B
    Expert Opin Pharmacother; 2011 Sep; 12(13):1985-98. PubMed ID: 21790503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.